Artrya Limited (ASX:AYA)
Australia · Delayed Price · Currency is AUD | Market Cap | 765.44M +786.6% |
| Revenue (ttm) | 29.00K +123.1% |
| Net Income | -19.71M |
| EPS | -0.17 |
| Shares Out | 159.80M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 223,084 |
| Open | 4.770 |
| Previous Close | 4.770 |
| Day's Range | 4.700 - 4.900 |
| 52-Week Range | 0.605 - 5.240 |
| Beta | 0.64 |
| Analysts | Strong Buy |
| Price Target | 6.14 (+28.18%) |
| Earnings Date | Aug 20, 2026 |
About Artrya
Artrya Limited, a medical technology company, engages in the development and commercialization of artificial intelligence platform that detects, diagnoses, and address coronary artery disease in Australia. The company offers Salix, a suite ifcloud-based software that uses artificial intelligence to automate the detection of coronary artery disease from coronary computed tomography angiography scans to identify and manage patients at risk of a heart attack. Artrya Limited was incorporated in 2018 and is based in West Perth, Australia. [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for AYA stock is "Strong Buy." The 12-month stock price target is $6.14, which is an increase of 28.18% from the latest price.
News
Artrya Quarterly report: H1 2026
Artrya has published its H1 2026 quarterly earnings report on February 24, 2026.
Artrya Earnings Call Transcript: Q2 2026
Converted all U.S. foundation partners to commercial contracts, launched first Plaque module revenues, and secured six major SAPPHIRE study sites. Strong cash position of AUD 76.5 million supports FDA submission and U.S. expansion, with full customer ramp-up targeted for FY 2027.
Artrya Quarterly report: Q2 2026
Artrya has published its Q2 2026 quarterly earnings report on February 1, 2026.
Artrya Transcript: Bell Potter Healthcare Conference 2025
A real-time, AI-driven coronary CT platform is set to transform cardiac care by streamlining hospital workflows, improving patient outcomes, and delivering strong financial returns. With foundation customers committed and a robust U.S. go-to-market plan, break-even is targeted by FY2027.
Artrya Transcript: AGM 2025
The AGM highlighted a successful transition to commercial operations, strong U.S. market entry, and robust financial planning. Key FDA clearances, strategic partnerships, and a focus on high-margin SaaS growth were discussed, with profitability targeted for FY 2027-2028.
Artrya Slides: FY 2025
Artrya has posted slides in relation to its FY 2025 quarterly earnings report, which was published on November 12, 2025.
Artrya Earnings Call Transcript: Q1 2026
Technical integration and commercial negotiations with U.S. partners are progressing, with FDA clearance for the Salix Coronary Plaque module and a strong $80 million capital raise supporting U.S. expansion. Cash outflows rose due to scaling, but the company remains well-funded and targets break-even by FY2027.
Artrya Earnings release: Q1 2026
Artrya released its Q1 2026 earnings on October 28, 2025, summarizing the period's financial results.
Artrya Annual report: H2 2025
Artrya has published its H2 2025 annual report on October 12, 2025.
Artrya Slides: Company Presentation
Artrya has posted slides in relation to its latest quarterly earnings report, which was published on August 31, 2025.
Artrya Transcript: FDA Announcement
FDA clearance of the Salix Coronary Plaque Module enables real-time, automated plaque analysis at the point of care, opening a $4.4 billion U.S. market opportunity. The company is focused on structured rollout, reimbursement optimization, and expanding clinical studies, with first revenues expected in Q4 and further product submissions planned.
Artrya Press release: FDA Announcement
Artrya issued a press release on August 21, 2025, disclosing material business information to investors.
Artrya Earnings Call Transcript: Q4 2025
Transitioning to commercial operations, the company secured its first U.S. deal and is expanding partnerships in both the U.S. and Australia. FDA clearance for the plaque module and the SAPPHIRE study launch are key near-term priorities, with strong market interest and a solid cash position.
Artrya Earnings release: Q4 2025
Artrya released its Q4 2025 earnings on July 28, 2025, summarizing the period's financial results.